Can-Fite BioPharma (NYSE:CANF) Stock Rating Upgraded by StockNews.com

Can-Fite BioPharma (NYSE:CANF) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Tuesday.

Separately, EF Hutton Acquisition Co. I upgraded shares of Can-Fite BioPharma to a “strong-buy” rating in a research note on Wednesday, July 17th.

Can-Fite BioPharma Price Performance

CANF stock opened at $2.92 on Tuesday. Can-Fite BioPharma has a 1-year low of $1.81 and a 1-year high of $4.69. The business has a 50-day moving average price of $2.29 and a 200 day moving average price of $2.51. The company has a market capitalization of $10.32 million, a P/E ratio of -1.63 and a beta of 1.41.

Institutional Trading of Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC grew its holdings in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 518,853 shares of the company’s stock after acquiring an additional 136,055 shares during the period. Armistice Capital LLC owned about 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent quarter. 21.00% of the stock is owned by hedge funds and other institutional investors.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.